Citius Oncology Inc (CTOR)

Apr 02, 2026

CTXR Stock Price, Quote & Chart | CITIUS PHARMACEUTICALS INC (NASDAQ:CTXR) - ChartMill

Apr 02, 2026

Apr 01, 2026

Citius Oncology reports 86% response rate in lymphoma study By Investing.com - Investing.com India

Apr 01, 2026

Apr 01, 2026

CTOR Stock Price, Quote & Chart | CITIUS ONCOLOGY INC (NASDAQ:CTOR) - ChartMill

Apr 01, 2026

Apr 01, 2026

Citius Oncology reports early adoption metrics for lymphoma drug By Investing.com - Investing.com South Africa

Apr 01, 2026

Mar 31, 2026

Citius Oncology highlights early LYMPHIR commercial traction, expansion - TipRanks

Mar 31, 2026

Mar 31, 2026

Citius Oncology advances LYMPHIR launch and global expansion - TipRanks

Mar 31, 2026

Mar 31, 2026

Citius Oncology reports strong early LYMPHIR launch with broad payer coverage and institutional uptake - TradingView

Mar 31, 2026

Mar 31, 2026

Citius Oncology reports early adoption metrics for lymphoma drug - Investing.com

Mar 31, 2026

Mar 31, 2026

Citius Oncology Provides Commercial Update on LYMPHIR™ Launch Highlighting Early Adoption and Expanding Clinical Development - PR Newswire

Mar 31, 2026

Mar 31, 2026

Can Citius Oncology Inc keep up with sector leaders2026 Pullbacks & Risk Managed Investment Entry Signals - baoquankhu1.vn

Mar 31, 2026

Mar 27, 2026

Aug PreEarnings: Should you avoid Sionna Therapeutics Inc stock right now2026 Catalysts & High Conviction Buy Zone Picks - baoquankhu1.vn

Mar 27, 2026

Mar 26, 2026

Institution Moves: Can Citius Oncology Inc lead its sector in growthTrade Exit Summary & Fast Gain Stock Tips - baoquankhu1.vn

Mar 26, 2026

Mar 24, 2026

Citius Oncology to Participate in USCLC Annual Workshop 2026, Hi - GuruFocus

Mar 24, 2026

Mar 24, 2026

Citius Oncology to Participate in USCLC Annual Workshop 2026, Highlighting LYMPHIR™ in Discussions with Leading Cutaneous Lymphoma Experts - Nasdaq

Mar 24, 2026

Mar 24, 2026

Citius Oncology (NASDAQ:CTOR) Trading Down 2.8%Here's What Happened - MarketBeat

Mar 24, 2026

Mar 23, 2026

Citius Oncology (CTOR) expands Lymphir distribution to Europe through exclusive agreement with Uniphar - MSN

Mar 23, 2026

Mar 22, 2026

If You Invested $1,000 in Citius Pharmaceuticals Inc (CTXR) - stocktitan.net

Mar 22, 2026

Mar 20, 2026

Citius Oncology inks exclusive European distribution pact with Uniphar - MSN

Mar 20, 2026

Mar 20, 2026

Citius Oncology, Inc.: Fundamental Analysis and Financial Ratings | CTOR | US17331Y1091 - marketscreener.com

Mar 20, 2026

Mar 17, 2026

Activity Recap: Will Citius Oncology Inc outperform small cap indexes2026 Opening Moves & Safe Entry Trade Reports - baoquankhu1.vn

Mar 17, 2026

Mar 17, 2026

CTORCitius Oncology, Inc. Latest Stock News & Market Updates - Stock Titan

Mar 17, 2026

Mar 16, 2026

CTOR Stock Price and Chart — NASDAQ:CTOR - TradingView

Mar 16, 2026

Mar 14, 2026

Analysts Offer Insights on Healthcare Companies: Citius Oncology (CTOR) and Oruka Therapeutics (ORKA) - The Globe and Mail

Mar 14, 2026

Mar 13, 2026

Citius Oncology reports positive phase 1 trial data for LYMPHIR By Investing.com - Investing.com Nigeria

Mar 13, 2026

Mar 10, 2026

Citius Oncology reports positive phase 1 trial data for LYMPHIR - Investing.com Australia

Mar 10, 2026

Mar 10, 2026

Citius Highlights Positive LYMPHIR Phase 1 Gynecologic Cancer Data - TipRanks

Mar 10, 2026

Mar 10, 2026

Citius Oncology Reports Positive Phase 1 LYMPHIR Combination Data - TipRanks

Mar 10, 2026

Mar 10, 2026

Citius reports positive Phase 1 topline: 24% ORR, 48% CBR for LYMPHIR + pembrolizumab in gynecologic cancers - TradingView

Mar 10, 2026

Mar 10, 2026

Citius Oncology Announces Positive Topline Results from Investig - GuruFocus

Mar 10, 2026

Mar 10, 2026

Citius Oncology, Inc. Announces Positive Topline Results from Investigator-Initiated Phase 1 Study of Lymphir in Combination with Pembrolizumab in Relapsed or Refractory Gynecologic Cancers - marketscreener.com

Mar 10, 2026

Mar 10, 2026

Citius Oncology Announces Positive Topline Results from Investigator‑Initiated Phase 1 Study of LYMPHIR™ in Combination with Pembrolizumab in Relapsed or Refractory Gynecologic Cancers - PR Newswire

Mar 10, 2026

Mar 07, 2026

Aug EndMonth: Can Citius Oncology Inc lead its sector in growthPortfolio Risk Summary & Accurate Entry and Exit Point Alerts - baoquankhu1.vn

Mar 07, 2026

Mar 06, 2026

Aug Highlights: Does Citius Oncology Inc have strong fundamentalsMarket Risk Analysis & Weekly Breakout Opportunity Watchlist - baoquankhu1.vn

Mar 06, 2026

Mar 06, 2026

Citius Pharma (CTXR) Becomes Revenue-Generating With the Commercial Launch of LYMPHIR - Finviz

Mar 06, 2026

Mar 04, 2026

Citius Oncology reports 86% response rate in lymphoma study - Investing.com

Mar 04, 2026

Mar 04, 2026

Citius Oncology, Inc. announces preliminary topline data from its study in high-risk diffuse large B-cell lymphoma patients - Bitget

Mar 04, 2026

Mar 04, 2026

Citius Oncology Reports Positive LYMPHIR Phase 1 CAR-T Data - TipRanks

Mar 04, 2026

Mar 04, 2026

Citius Oncology Announces Positive Phase 1 LYMPHIR Data - TipRanks

Mar 04, 2026

Mar 04, 2026

Citius Oncology (Nasdaq: CTXR) reports encouraging early LYMPHIR CAR-T combo results - stocktitan.net

Mar 04, 2026

Mar 04, 2026

Citius Oncology reports 86% ORR and favorable safety for LYMPHIR prior to commercial CAR‑T in high‑risk DLBCL - TradingView

Mar 04, 2026

Mar 04, 2026

Citius Oncology Announces Preliminary Topline Phase 1 Data from Study of LYMPHIR™ (E7777) Dosing Prior to Commercial CAR‑T Therapy in High‑Risk Diffuse Large B‑Cell Lymphoma – Company Announcement - Financial Times

Mar 04, 2026

Mar 02, 2026

Citius Oncology, Inc. (NASDAQ:CTOR) Short Interest Update - MarketBeat

Mar 02, 2026

Feb 24, 2026

Citius Oncology (CTOR) Expands LYMPHIR Distribution to Europe Through Exclusive Agreement With Uniphar - Finviz

Feb 24, 2026